Diagenode

Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer


Wang W. et al.

Transcription factors play a key role in the development of diverse cancers, and therapeutically targeting them has remained a challenge. In prostate cancer, the gene encoding the transcription factor ERG is recurrently rearranged and plays a critical role in prostate oncogenesis. Here, we identified a series of peptides that interact specifically with the DNA binding domain of ERG. ERG inhibitory peptides (EIPs) and derived peptidomimetics bound ERG with high affinity and specificity, leading to proteolytic degradation of the ERG protein. The EIPs attenuated ERG-mediated transcription, chromatin recruitment, protein-protein interactions, cell invasion and proliferation, and tumor growth. Thus, peptidomimetic targeting of transcription factor fusion products may provide a promising therapeutic strategy for prostate cancer as well as other malignancies.

Tags
HighCell ChIP kit
IPure kit

Share this article

Published
April, 2017

Source

Products used in this publication

  • ChIP kit icon
    C01010063
    HighCell# ChIP kit protein G
  • default alt
    C03010015
    IPure kit v2

Events

  • Plant Genomics and Gene Editing Congress
    Rotterdam
    May 21-May 22, 2019
 See all events

Applications

 See all applications



The European Regional Development Fund and Wallonia are investing in your future.

Extension of industrial buildings and new laboratories.



  ABOUT SSL CERTIFICATES

         Site map   |   Contact us   |   Conditions of sales   |   Conditions of purchase   |   Privacy policy   |   Diagenode Diagnostics

?>